Nandrolone
- Atc Codes:A14AB01#S01XA11
- CAS Codes:360-70-3#62-90-8
- PHARMGKB ID:360-70-3#62-90-8
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Substrate of
- Induces
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Deca-Durabolin; Belgium: Deca-Durabolin; Cyprus: Deca-Durabolin; Czech Republic: Deca-Durabolin; Estonia: Retabolil; Finland: Deca-Durabolin; Greece: Deca-Durabolin; Hungary: Retabolil; Ireland: Deca-Durabolin; Italy: Deca-Durabolin; Latvia: Retabolil; Lithuania: Retabolil; Luxembourg: Deca-Durabolin; Netherlands: Deca-Durabolin; Poland: Deca-Durabolin; Portugal: Deca-Durabolin; Slovakia: Deca-Durabolin, Superanarubolon; Slovenia: Deca-Durabolin; Spain: Deca-Durabolin; UK: Deca-Durabolin.
North America
Canada: Deca-Durabolin. USA: Nandrolone decanoate.
Latin America
Argentina: Deca-Durabolin; Brazil: Deca-Durabolin; Mexico: Deca-Durabolin.
Asia
Japan: Deca Durabolin, Deca Duramin.
Drug combinations
Chemistry
Nandrolone Decanoate: C~28~H~44~O~3~. Mw: 428.65. (1) Estr-4-en-3-one, 17-[(1-oxodecyl)oxy]-, (17β)-; (2) 17β-Hydroxyestr-4-en-3-one decanoate. CAS-360-70-3 (1965).
Nandrolone Phenpropionate: C~27~H~34~O~3~. Mw: 406.56. Estr-4-en-3-one, 17-(1-oxo-3-phenylpropoxy)-. CAS-62-90-8.
Pharmacologic Category
Hormones and Synthetic Substitutes; Androgens. (ATC-Code: A14AB01; S01XA11).
Mechanism of action
Promotes tissue-building processes, increases production of erythropoietin, causes protein anabolism, increases hemoglobin and red blood cell volume.
Therapeutic use
Control of metastatic breast cancer. Management of anemia of renal insufficiency.
Pregnancy and lactiation implications
Contraindicated in pregnant and nursing women.
Unlabeled use
Contraindications
Hypersensitivity to nandrolone or any component of the formulation. Carcinoma of breast or prostate. Nephrosis. Pregnancy. Not for use in infants.
Warnings and precautions
Use with caution in hepatic impairment. Anabolic steroids might cause peliosis hepatis or liver cell tumors which may not be apparent until liver failure or intra-abdominal hemorrhage develops. May cause blood lipid changes with increased risk of arteriosclerosis. Use with caution in breast cancer (may cause hypercalcemia by stimulating osteolysis), diabetes mellitus, and in conditions influenced by edema (e.g. cardiovascular disease, migraine, seizure disorder, renal impairment).